Pfizer’s COVID-19 Pill Reduces Hospitalisation And Death By 89%

Pfizer’s COVID-19 Pill Reduces Hospitalisation And Death By 89%

Pfizer announced on Friday that its experimental coronavirus-fighting tablet decreased the risk of hospitalization and death by 89 percent.

Pfizer thinks that by combining the pill with ritonavir, an earlier antiviral medicine that can be taken at home, individuals may be able to get better before they need to travel to the hospital.

According to the business, an interim study conducted before the trial was set to end found that COVID-19 reduced the risk of hospitalization or death by 89 percent if given to patients in a timely manner.

Although Pfizer disclosed these results in a news release, it did not provide scientists to discuss the data ahead of release. Also, the data has not been peer-reviewed or published.

The company noted that more specifics in a peer-reviewed paper will be shared soon, adding that it will be submitted to the US Food and Drug Administration.

In other news, the United Kingdom has become the first country in the world to approve a COVID-19 antiviral pill, molnupiravir, jointly developed by Merck and Ridgeback Biotherapeutics.

On Thursday, the Medicines and Healthcare products Regulatory Agency (MHRA) recommended that the potentially game-changing drug be used as soon as possible following a positive COVID-19 test and within five days of the onset of symptoms, citing clinical data.

Molnupiravir is the first oral antiviral treatment for COVID-19 to be approved, marking a boost to the fight against the pandemic.

The green lights are coming from potential regulatory clearance in the United States as advisers of the country will meet this month to vote on whether molnupiravir should be authorised.

↯↯↯Read More On The Topic On TDPel Media Below↯↯↯

»Share Your Opinion On TDPel Media«